A Study to Assess the Absolute Bioavailability of oral Selumetinib in Healthy Male Volunteers.

Study identifier:D1532C00080

ClinicalTrials.gov identifier:NCT02238782

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Selumetinib with Respect to an Intravenous Microdose of [14C] Selumetinib in Healthy Male Volunteers

Medical condition

Healthy volunteers bioavailability study

Phase

Phase 1

Healthy volunteers

Yes

Study drug

selumetinib 75mg single dose

Sex

Male

Actual Enrollment

21

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Oct 2014
Primary Completion Date: 01 Nov 2014
Study Completion Date: 01 Nov 2014

Study design

Allocation: N/A
Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Mar 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria